TCG Crossover Management »

Aeglea Biotherapeutics shares owned by TCG Crossover Management

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by TCG Crossover Management from 13F filings

Historical chart of TCG Crossover Management investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by TCG Crossover Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $18M 1.1M 16.76

More positions owned by TCG Crossover Management

Abivax Sa American Depositary Shares Adrs (ABVX)
Cg Oncology Comm (CGON)
Cogent Biosciences Comm (COGT)
Amylyx Pharmaceuticals Comm (AMLX)
Centessa Pharmaceuticals Adrs (CNTA)
Tango Therapeutics Comm (TNGX)
Ocular Therapeutix Comm (OCUL)
Dianthus Therapeutics Comm (DNTH)
Tourmaline Bio Comm (TRML)
Dyne Therapeutics Comm (DYN)
Agios Pharmaceuticals Comm (AGIO)
Eyepoint Pharmaceuticals Comm (EYPT)
Fulcrum Therapeutics Comm (FULC)
Savara Comm (SVRA)
Rapt Therapeutics Comm (RAPT)

View all positions for TCG Crossover Management

Top funds holding Aeglea Biotherapeutics

FMR
Fairmount Funds Management
BlackRock
Rtw Investments
Tang Capital Management
Vanguard Group
VR Adviser
Braidwell
Capital Research and Management Company - Division 3
Driehaus Capital Management
Commodore Capital
State Street Corporation
Wellington Management Company
Paradigm Biocapital Advisors
Affinity Asset Advisors

View all funds holding Aeglea Biotherapeutics